| Followers | 74 |
| Posts | 1809 |
| Boards Moderated | 0 |
| Alias Born | 04/02/2010 |
Monday, July 02, 2012 12:01:47 PM
12-12553-jmp Doc 13 Filed 06/29/12 Entered 06/29/12 10:38:01 Main DocumentPg 19 of 21
25.
Final Hearing.
The Final Hearing is scheduled for July 24, 2012 at 10:00 a.m.prevailing Eastern time, before this Court (the “Final Hearing”). On or before July 6, 2012, theDebtor shall serve, by United States mail, first-class postage prepaid, notice of the entry of thisInterim Order and of the Final Hearing (the “Hearing Notice”), together with a copy of thisInterim Order and the Motion, on: (a) the parties having been given notice of the InterimHearing; (b) any party which has filed prior to such date request for notices with this Court; (c)counsel for any statutory committee appointed in this Case; and (d) the twenty (20) largestunsecured creditors. The Hearing Notice shall state that any party in interest objecting to the relief requested in the Motion on a further interim or final basis shall file written objections withthe Clerk of the Court no later than July 17, 2012 at 4:00 p.m. (prevailing Eastern Time), withrespect to the Final Order, which objections shall be served so as to be received on or beforesuch dates by: (i) counsel to the Debtor; (ii) counsel to any statutory committee appointed in thisCase; (iii) counsel to the Prepetition Lenders, Olshan Frome Wolosky LLP, 65 E. 55
th Street, New York, New York 10022, Attn: Adam H. Friedman, Esq. and Jonathan T. Koevary, Esq.; and(iv) the Office of the United States Trustee.
"All Truth, In The Long Run, Is Only Common Sense Clarified. ~ Thomas H. Huxley
"Facts Do Not Cease To Exist Because They Are Ignored." ~ Aldous Huxley
Recent PTIX News
- Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114 • ACCESS Newswire • 03/17/2026 12:00:00 PM
- Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market • ACCESS Newswire • 03/10/2026 12:00:00 PM
- Results from Phase 1 Multiple-Dose Study of PT00114 • ACCESS Newswire • 12/09/2025 01:46:00 PM
- Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice • ACCESS Newswire • 11/27/2025 08:45:00 AM
- Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study • ACCESS Newswire • 11/13/2025 01:22:00 PM
- Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates • GlobeNewswire Inc. • 07/30/2025 12:30:00 PM
- Nasdaq Top 5 Premarket Losers • IH Market News • 05/20/2025 12:47:37 PM
- Protagenic Therapeutics Soars 190% on Merger to Launch Neuroactive Biopharma Firm • IH Market News • 05/19/2025 02:28:09 PM
- Nasdaq Top 5 Premarket Gainers • IH Market News • 05/19/2025 01:07:08 PM
